B cell-targeted therapies in Sjögren's syndrome

Autoimmunity Reviews

Volumn 9, Issue 4, 2010, Pages 224-228

  Tobón, Gabriel J ^a,b   Pers, Jacques Olivier ^a,b   Youinou, Pierre ^a,b   Saraux, Alain ^a,b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

B cell; BAFF; Epratuzumab; Rituximab; Sj gren's syndrome

Indexed keywords

APRIL PROTEIN; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR RECEPTOR; BELIMUMAB; BLYS ANTIBODY; BRIOBACEPT; CD20 ANTIGEN; CD22 ANTIGEN; CLEMASTINE; CYCLOPHOSPHAMIDE; CYTOKINE; EPRATUZUMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; B LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL; DISEASE COURSE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART PALPITATION; HUMAN; HYPOTENSION; INJECTION SITE REACTION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; REVIEW; SERUM SICKNESS; SJOEGREN SYNDROME; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD22; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; PROTEIN ENGINEERING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; SJOGREN'S SYNDROME;

EID: 73849103553     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.08.001     Document Type: Review

References (40)

1. Moutsopoulos H.M. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 72 (1994) 162-165
2. Tzioufas A.G., and Voulgarelis M. Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 21 (2007) 989-1010
3. Vitali C., Bombardieri S., Moutsopoulos H.M., Balestrieri G., Bencivelli W., Bernstein R.M., et al. Classification criteria for Sjögren's syndrome. A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002) 554-558
4. Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol 18 (2004) 249-269
5. Voulgarelis M., Dafni U.G., Isenberg D.A., and Moutsopoulos H.M. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 42 (1999) 1765-1772
6. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 46 (2002) 2160-2171
7. Daridon C., Guerrier T., Devauchelle V., Saraux A., Pers J.O., and Youinou P. Polarization of B effector cells in Sjögren's syndrome. Autoimmun Rev 6 (2007) 427-431
8. Le Pottier L., Devauchelle V., Pers J.O., Jamin C., and Youinou P. The mosaic of B-cell subsets (with special emphasis on primary Sjögren's syndrome). Autoimmun Rev 6 (2007) 149-154
9. Pers J.O., Le Pottier L., Devauchelle V., Saraux A., and Youinou P. B lymphocytes in Sjögren's syndrome. Rev Med Interne 29 (2008) 1000-1006
10. Le Pottier L., Devauchelle V., Fautrel A., Daridon C., Saraux A., Youinou P., et al. Ectopic germinal centers are rare in Sjögren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 15 (2009) 3540-3547
11. d'Arbonneau F., Pers J.O., Devauchelle V., Pennec Y., Saraux A., and Youinou P. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum 54 (2006) 115-126
12. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109 (2002) 59-68
13. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 1050 (2005) 34-39
14. Binard A., Le Pottier L., Devauchelle-Pensec V., Saraux A., Youinou P., and Pers J.O. Is the blood B-cell subset profile diagnostic for Sjögren's syndrome. Ann Rheum Dis 68 (2009) 1447-1452
15. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., and Ledbetter J.A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7 (1988) 711-717
16. Valentine M.A., Meier K.E., Rossie S., and Clark E.A. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264 (1989) 11282-11287
17. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., and Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63 (1984) 1424-1433
18. Tedder T.F., Boyd A.W., Freedman A.S., Nadler L.M., and Schlossman S.F. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135 (1985) 973-979
19. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15 (1994) 450-454
20. Press O.W., Appelbaum F., Ledbetter J.A., Martin P.J., Zarling J., Kidd P., et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69 (1987) 584-591
21. Engel P., Nojima Y., Rothstein D., Zhou L.J., Wilson G.L., Kehrl J.H., et al. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils and monocytes. J Immunol 150 (1993) 47:19-4732
22. Tedder T.F., Poe J.C., and Haas K.M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88 (2005) 1-50
23. Sato S., Miller A.S., Inaoki M., Bock C.B., Jansen P.J., Tang M.L.K., et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5 (1996) 551-562
24. O'Keefe T.L., Williams G.T., Batista F.D., and Neuberger M.S. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189 (1999) 1307-1313
25. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189 (1999) 1747-1756
26. Mackay F., and Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2 (2002) 465-475
27. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 (1999) 1697-1710
28. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
29. Becker Y.T., Becker B.N., Pirsch J.D., and Sollinger H.W. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4 (2004) 996-1001
30. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64 (2005) 913-920
31. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 66 (2007) 351-357
32. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjögren's syndrome. Arthritis Rheum 52 (2005) 2740-2750
33. Galarza C., Valencia D., Tobón G.J., Zurita L., Mantilla R.D., Pineda-Tamayo R., et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allergy Immunol 34 (2008) 124-128
34. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjögren's syndrome after two infusions of rituximab (Anti-CD20). Arthritis Rheum 57 (2007) 310-317
35. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 56 (2007) 1464-1477
36. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 56 (2007) 1134-1144
37. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomized, double-blind, placebo controlled pilot study. Ann Rheum Dis 67 (2008) 1541-1544
38. Steinfeld S.D., Tant L., Burmester G.R., Teoh N.K., Wegener W.A., Goldenberg D.M., et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8 (2006) R129
39. Furie R., Stohl W., Ginzler E.M., Becker M., Mishra N., Chatham W., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 10 (2008) R109
40. García-Carrasco M., Jiménez-Hernández M., Escárcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 8 (Feb 2009) 343-348